Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Point mutations in AML1/RUNX1 are prevalent in myelodysplastic syndrome (MDS) and MDS-related acute myeloid leukemia (MDS/AML).
• These mutations are considered disease-defining genetic abnormalities, impacting AML1/RUNX1 function.
• While most mutants lose trans-activation, N-terminal (Ni-type) and C-terminal (Ct-type) mutants exhibit dominant-negative effects, suggesting oncogenic potential.

Purpose of the Study:

• To investigate the distinct molecular mechanisms and pathogenic roles of Ni-type and Ct-type AML1/RUNX1 mutants in MDS/AML.
• To elucidate how these different mutant types contribute to the specific clinical features observed in MDS/AML patients.
• To explore the oncogenic potential and cellular effects of specific AML1/RUNX1 mutants.

Main Methods:

• Analysis of AML1/RUNX1 point mutations across the entire gene length.
• Biological analysis using a mouse bone marrow transplantation model with Ni-type (D171N) and Ct-type (S291fsX300) mutants.
• In vitro studies using human CD34(+) cells to assess molecular mechanisms and cellular behavior.

Main Results:

• Ni-type and Ct-type AML1/RUNX1 mutants demonstrate distinct molecular mechanisms in human CD34(+) cells.
• Ni-type mutants induce a differentiation block without promoting cell growth, but BMI-1 co-expression leads to increased blast cells.
• Ct-type mutants exhibit intrinsic proliferation ability, contributing to MDS pathogenesis by inhibiting hematopoietic stem cell differentiation.

Conclusions:

• AML1/RUNX1 mutants are central to MDS/AML pathogenesis, acting as initiating factors.
• Both Ni-type and Ct-type mutants inhibit hematopoietic stem cell differentiation, initiating MDS.
• Ni-type mutants require additional oncogenic events (like BMI-1 expression) to acquire proliferative capacity, while Ct-type mutants possess inherent proliferation ability.